JohnTKisselMD

PubMed

• 389 citations
  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-bli...
  James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn
  The Lancet. Neurology. 2017-12-01
• 16 citations
  Facioscapulohumeral muscular dystrophy functional composite outcome measure.
  Katy Eichinger, Chad Heatwole, Stanley Iyadurai, Wendy King, Lindsay Baker
  Muscle & Nerve. 2018-01-30
• 120 citations
  Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy.
  John T. Kissel, Michael P. McDermott, J. R. Mendell, Wendy King, Shree Pandya
  Neurology. 2001-10-23

Journal Articles

• Project Cure SMA Investigators Network Reliability and validity of the TIMPSI for infants with spinal muscular atrophy type 1  
  Krosschell KJ, Maczulski JA, Scott C, King W, Hartman JT, Case LE, Viazzo-Trussell D, Wood J, Roman CA, Hecker E, Meffert M, Leveille M, Kienitz K, Swoboda KJ, Pediatr Phys Ther, 1/1/2013
• VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy  
  Ramachandran N, Munteanu I, Wang P, Ruggieri A, Rilstone JJ, Israelian N, Naranian T, Paroutis P, Guo R, Ren ZP, Nishino I, Chabrol B, Pellissier JF Minetti C, Udd B, ..., Acta Neuropathol, 1/1/2013
• Muscle Study Group Role of disease severity, illness perceptions, and mood on quality of life in muscle disease  
  Rose, MR, Sadjadi R, Weinman J, Akhtar T, Pandya S, Kissel JT, Jackson CE, Muscle Nerve, 1/1/2012
• Validation of the individualized neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK  
  Sadjadi S, Vincent KA, Carr AJ, Walburn J, Brooks VL, Pandya S, Kissel JT, Jackson CE, Rose MR, Muscle Study Group, Health and Quality of Life Outcomes, 12/1/2011
• A randomized, pilot trial of etanercept in dermatomyositis  
  The Muscle Study Group, Ann Neurol, 1/1/2011
• Impaired myocardial perfusion reserve  
  Raman SV, Phatak K, Hoyle C, Pennell ML, McCarthy B, Tran T, Prior TW, Olesik J, Lutton A, Rankin C, Kissel JT, al-Dahhak R, European Heart Journal, 1/1/2011
• SMA CARNI-VAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy  
  Kissel JT, Scott CB, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, Acsadi G, Elsheikh B, Schroth MK, D’Anjou G, LaSalle B, Prior TW, Sorenson S, Maczulski MA, Bromb..., PLoS ONE, 1/1/2011
• Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy (letter)  
  King WK, Kissel JT, Neurology, 1/1/2010
• The diagnosis and management of Duchenne muscular dystrophy-part 1 Diagnosis, pharmacological and psychosocial managem  
  Bushby, Finkel R, Birnkrant DJ, Case LE, Clemens P, Cripe L, Kaul A, Kinett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, DMD Care Considerat..., Lancet Neurology, 1/1/2010
• The diagnosis and management of Duchenne muscular dystrophy-part 2 Implementation of multidisciplinary care  
  Bushby, Finkel R, Birnkrant DJ, Case LE, Clemens P, Cripe L, Kaul A, Kinett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, DMD Care Considerat..., Lancet Neurology, 1/1/2010
• Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial  
  Aggarwal SP, Zinman L, Simpson E, McKinley, Jackson KE, Pinto H, Kaufman P, Conwit RA, Schoenfeld D, Shefner J, Cudkowicz M, Northeast and Canadian Amyotrophic Lateral..., Lancet Neurology, 1/1/2010
• Arachnocerebellum and HIV infection  
  Elsheikh B, Maher WE, Kissel JT, Arch Neurol, 1/1/2010
• SMA CARNI-VAL TRIAL PART I: Double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy  
  Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, Acsadi G, Elsheikh B, Schroth MK, D’Anjou G, LaSalle B, Prior TW, Sorenson S, Maczulski MA, Brom..., PLoS ONE, 1/1/2010
• Peripheral Nerve Society Guideline on the classification, diagnosis, investigation and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary  
  Collins MP, Dyck PJB, Gronseth GS, Guillevin L, Hadden RDM, Heuss D, Leger J-M, Notermans NC, Pollard JD, Said G, Soue G, Vrancken AFJE, Kissel, JT, J Periph Nerv Sys, 1/1/2010
• Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy  
  Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupler E, Lou JS, Ensrud E, Tan E, Goldstein JM, Katz J, Dimachkie MM, Barohn RJ, Mo..., J Neuropathol Exp Neurol, 1/1/2010
• An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy  
  Elsheikh B, Prior T, Zhang X, Miller R, Kolb SJ, Moore D, Bradley W, Barohn R, Bryan W, Gelinas D, Iannoccone S, Leshner R, Mendell J, Mendoza M, Russman B, Smith S, K..., Muscle & Nerve, 1/1/2009
• Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker Muscular Dystrophy  
  Kaspar RW, Allen HD, Ray WC, Alvarez CE, Kissel JT, Pestronk A, Weiss RB, Flanigan, KM, Mendell JR, Montanaro R, Circulation: Cardiovascular Genetics, 1/1/2009
• Spinal angiography and epidural venography in Hirayama disease  
  Elsheikh B, Kissel JT, Christoforidis G, Wicklund M, Kehagias DT, Chiocca EA, Mendell JR, Muscle Nerve, 1/1/2009
• ALSUntangled update 1: Investigating a bug (Lyme disease) and a drug (Iplex) on behalf of people with ALS  
  The ALSUtangled Group, Amyotrophic Lateral Sclerosis, 1/1/2009
• Phase I/II open label study of valproic acid in spinal muscular atrophy  
  Swoboda KJ, Prior TW, Scott CB, Chan B, LaSalle B, Reyna SP, Wood J, Hang M, Acsadi G, Crawford TO, Kissel JT, Krosschell K, D’Anjou G, Bromberg MB, Schroth M, Simard ..., PLoS ONE, 1/1/2009
• Polymyositis: Not a unicorn or mythological beast…but maybe a duck?  
  Kissel JT, Neurology, 1/1/2008
• Comparison of outcome measures from a trial of mycophenylate mofetil in myasthenia gravis  
  Wolfe GI, Barohn RJ, Sanders DB, McDermott MP, and the Muscle Study Group, Muscle Nerve, 1/1/2008
• Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis  
  Burns TM, Conaway MR, Cutter GR, Sanders DB, The Muscle Study Group, Muscle Nerve, 1/1/2008
• A disease-specific measure of quality of life for myasthenia gravis  
  Mullins LL, Carpentier MY, Paul RH, Sanders DB, Muscle Study Group, Muscle Nerve, 1/1/2008
• Phase II/III randomized trial of TCH346 in patients with ALS  
  R. Miller, W. Bradley, M. Cudkowicz, J. Hubble, V. Meininger, H. Mitsumoto, D.Moore, H. Pohlmann, D. Sauer, V. Silani, M. Strong, M. Swash, E. Vernotica and The TCH 34..., Neurology, 1/1/2007
• Join now to see all